JP2014511355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511355A5 JP2014511355A5 JP2013550656A JP2013550656A JP2014511355A5 JP 2014511355 A5 JP2014511355 A5 JP 2014511355A5 JP 2013550656 A JP2013550656 A JP 2013550656A JP 2013550656 A JP2013550656 A JP 2013550656A JP 2014511355 A5 JP2014511355 A5 JP 2014511355A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- hydroxy
- phenylcyclopropanecarboxamide
- optionally substituted
- cyclopropanecarboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 2-trifluoromethylphenyl Chemical group 0.000 claims 111
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 2
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 2
- MGHKSRFPIHRNPO-RBSFLKMASA-N (1r,2r,3r)-2-(1,2-benzoxazol-3-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C=2C3=CC=CC=C3ON=2)=CC=CC=C1 MGHKSRFPIHRNPO-RBSFLKMASA-N 0.000 claims 1
- CQHODFXKUQOFOM-MGPQQGTHSA-N (1r,2r,3r)-2-(1,3-dimethylpyrazol-4-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound CC1=NN(C)C=C1[C@@H]1[C@@H](C=2C=CC=CC=2)[C@H]1C(=O)NO CQHODFXKUQOFOM-MGPQQGTHSA-N 0.000 claims 1
- KPUUYUXGBUUSRY-RBSFLKMASA-N (1r,2r,3r)-2-(1-cyclopropylpyrazol-4-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C2=CN(N=C2)C2CC2)=CC=CC=C1 KPUUYUXGBUUSRY-RBSFLKMASA-N 0.000 claims 1
- PEEFWEPTDKHOQN-RBSFLKMASA-N (1r,2r,3r)-2-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C3OC(F)(F)OC3=CC=2)C(=O)NO)=CC=CC=C1 PEEFWEPTDKHOQN-RBSFLKMASA-N 0.000 claims 1
- URJLVXHCZQRHBV-BRWVUGGUSA-N (1r,2r,3r)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C3OCCOC3=CC=2)C(=O)NO)=CC=CC=C1 URJLVXHCZQRHBV-BRWVUGGUSA-N 0.000 claims 1
- ZVRAEVJPHJQADI-BRWVUGGUSA-N (1r,2r,3r)-2-(2-cyclopropylpyridin-4-yl)-3-(4-fluorophenyl)-n-hydroxycyclopropane-1-carboxamide Chemical compound C=1C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC(F)=CC=2)=CC=NC=1C1CC1 ZVRAEVJPHJQADI-BRWVUGGUSA-N 0.000 claims 1
- LASRJNMPYOZRDP-BRWVUGGUSA-N (1r,2r,3r)-2-(2-cyclopropylpyridin-4-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C=1C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=NC=1C1CC1 LASRJNMPYOZRDP-BRWVUGGUSA-N 0.000 claims 1
- XOLGCEWZVMNXSP-RBSFLKMASA-N (1r,2r,3r)-2-(2-cyclopropylpyrimidin-5-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound N1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CN=C1C1CC1 XOLGCEWZVMNXSP-RBSFLKMASA-N 0.000 claims 1
- MMWFLIBCIOFXBI-BZUAXINKSA-N (1r,2r,3r)-2-(5-chloro-2,3-dihydro-1,4-benzodioxin-7-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C3OCCOC3=C(Cl)C=2)C(=O)NO)=CC=CC=C1 MMWFLIBCIOFXBI-BZUAXINKSA-N 0.000 claims 1
- YPYUDQCOXWXJPZ-BZUAXINKSA-N (1r,2r,3r)-2-(6-cyclopropylpyridazin-4-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C=1C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CN=NC=1C1CC1 YPYUDQCOXWXJPZ-BZUAXINKSA-N 0.000 claims 1
- MNTNIJLMDQXLQZ-BRWVUGGUSA-N (1r,2r,3r)-2-(8-chloro-1,2,3,4-tetrahydroquinolin-6-yl)-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C3CCCNC3=C(Cl)C=2)C(=O)NO)=CC=CC=C1 MNTNIJLMDQXLQZ-BRWVUGGUSA-N 0.000 claims 1
- XWUSCGVMGNRCGU-HJNZIYBASA-N (1r,2r,3r)-2-[1-fluoro-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C2=CN3CCN(CC(F)(F)F)C(F)C3=C2)=CC=CC=C1 XWUSCGVMGNRCGU-HJNZIYBASA-N 0.000 claims 1
- KMAGHTJQITVHSQ-NJDAHSKKSA-N (1r,2r,3r)-2-[3-(6,7-dihydro-5h-pyrazolo[1,5-a]pyrimidin-4-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C(C=CC=2)N2C3=CC=NN3CCC2)C(=O)NO)=CC=CC=C1 KMAGHTJQITVHSQ-NJDAHSKKSA-N 0.000 claims 1
- JCGYZXWLLGBRBH-KZNAEPCWSA-N (1r,2r,3r)-2-[3-chloro-4-(5-methyl-1h-imidazol-2-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound N1C(C)=CN=C1C1=CC=C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)C=C1Cl JCGYZXWLLGBRBH-KZNAEPCWSA-N 0.000 claims 1
- FGLFPBNDHWBRRY-KZNAEPCWSA-N (1r,2r,3r)-2-[3-fluoro-4-(5-methyl-1h-imidazol-2-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound N1C(C)=CN=C1C1=CC=C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)C=C1F FGLFPBNDHWBRRY-KZNAEPCWSA-N 0.000 claims 1
- PCAXIDNUNZNULF-ZONZVBGPSA-N (1r,2r,3r)-2-[4-(1-benzyl-3,6-dihydro-2h-pyridin-4-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=C1C(CC1)=CCN1CC1=CC=CC=C1 PCAXIDNUNZNULF-ZONZVBGPSA-N 0.000 claims 1
- VFVVXZLMBWETAN-VAMGGRTRSA-N (1r,2r,3r)-2-[4-(2-cyclopropyl-1,3-oxazol-5-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=C1C(O1)=CN=C1C1CC1 VFVVXZLMBWETAN-VAMGGRTRSA-N 0.000 claims 1
- JLUNPOGVRYFTEO-KZNAEPCWSA-N (1r,2r,3r)-2-[4-(5-chloropyrimidin-2-yl)phenyl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=C1C1=NC=C(Cl)C=N1 JLUNPOGVRYFTEO-KZNAEPCWSA-N 0.000 claims 1
- TUXNUYPDRKJARN-BRWVUGGUSA-N (1r,2r,3r)-2-[5-chloro-6-(2-methyl-1,3-oxazol-5-yl)pyridin-3-yl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound O1C(C)=NC=C1C1=NC=C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)C=C1Cl TUXNUYPDRKJARN-BRWVUGGUSA-N 0.000 claims 1
- KRLRLQGBVIFKOE-VAMGGRTRSA-N (1r,2r,3r)-2-[5-chloro-6-(4-propan-2-ylpiperazin-1-yl)pyridin-3-yl]-n-hydroxy-3-phenylcyclopropane-1-carboxamide Chemical compound C1CN(C(C)C)CCN1C1=NC=C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)C=C1Cl KRLRLQGBVIFKOE-VAMGGRTRSA-N 0.000 claims 1
- BWLJEAAQXQRQLD-BZUAXINKSA-N (1r,2r,3r)-n-hydroxy-2-(1,5-naphthyridin-4-yl)-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C3=NC=CC=C3N=CC=2)C(=O)NO)=CC=CC=C1 BWLJEAAQXQRQLD-BZUAXINKSA-N 0.000 claims 1
- KKEQSTLHUXMHBH-JHJVBQTASA-N (1r,2r,3r)-n-hydroxy-2-(1-methylpyrazol-4-yl)-3-phenylcyclopropane-1-carboxamide Chemical compound C1=NN(C)C=C1[C@@H]1[C@@H](C=2C=CC=CC=2)[C@H]1C(=O)NO KKEQSTLHUXMHBH-JHJVBQTASA-N 0.000 claims 1
- WNNSPBYLDFFAJH-MCIONIFRSA-N (1r,2r,3r)-n-hydroxy-2-(2-methylphenyl)-3-(1-methylpyrazol-4-yl)cyclopropane-1-carboxamide Chemical compound CC1=CC=CC=C1[C@@H]1[C@@H](C2=CN(C)N=C2)[C@@H]1C(=O)NO WNNSPBYLDFFAJH-MCIONIFRSA-N 0.000 claims 1
- MFBADHRFGWIOHA-MGPQQGTHSA-N (1r,2r,3r)-n-hydroxy-2-(3-methylphenyl)-3-(1-methylpyrazol-4-yl)cyclopropane-1-carboxamide Chemical compound CC1=CC=CC([C@@H]2[C@H]([C@@H]2C(=O)NO)C2=CN(C)N=C2)=C1 MFBADHRFGWIOHA-MGPQQGTHSA-N 0.000 claims 1
- KRTKPTDSWQWEMF-KWIOBUNKSA-N (1r,2r,3r)-n-hydroxy-2-[1-methyl-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1h-pyrrolo[1,2-a]pyrazin-7-yl]-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C2=CN3CCN(CC(F)(F)F)C(C3=C2)C)C(=O)NO)=CC=CC=C1 KRTKPTDSWQWEMF-KWIOBUNKSA-N 0.000 claims 1
- ILEGKQBIIBREPC-BRWVUGGUSA-N (1r,2r,3r)-n-hydroxy-2-[1-oxo-2-(2,2,2-trifluoroethyl)-3h-isoindol-5-yl]-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C=2C=C3CN(CC(F)(F)F)C(=O)C3=CC=2)C(=O)NO)=CC=CC=C1 ILEGKQBIIBREPC-BRWVUGGUSA-N 0.000 claims 1
- ZPIKPSAPHYWKKS-KZNAEPCWSA-N (1r,2r,3r)-n-hydroxy-2-[3-(1,3-oxazol-5-yl)phenyl]-3-phenylcyclopropane-1-carboxamide Chemical compound C=1C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=CC=1C1=CN=CO1 ZPIKPSAPHYWKKS-KZNAEPCWSA-N 0.000 claims 1
- PYWCXCBMYMFPTR-KZNAEPCWSA-N (1r,2r,3r)-n-hydroxy-2-[4-(1,3-oxazol-5-yl)phenyl]-3-phenylcyclopropane-1-carboxamide Chemical compound C1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=C1C1=CN=CO1 PYWCXCBMYMFPTR-KZNAEPCWSA-N 0.000 claims 1
- PNBQXRCVDGVYGN-WXFUMESZSA-N (1r,2r,3r)-n-hydroxy-2-[4-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)phenyl]-3-phenylcyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C2=CC=C(C=C2)C=2C=C3OCCN(C3=CC=2)C)C(=O)NO)=CC=CC=C1 PNBQXRCVDGVYGN-WXFUMESZSA-N 0.000 claims 1
- BXLOSJKLGLNSSV-KZNAEPCWSA-N (1r,2r,3r)-n-hydroxy-2-[6-(2-methyl-1,3-oxazol-5-yl)pyridin-3-yl]-3-phenylcyclopropane-1-carboxamide Chemical compound O1C(C)=NC=C1C1=CC=C([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)C=N1 BXLOSJKLGLNSSV-KZNAEPCWSA-N 0.000 claims 1
- RYKOEXGARNYITG-KZNAEPCWSA-N (1r,2r,3r)-n-hydroxy-2-phenyl-3-(2-propan-2-yl-1,3-benzoxazol-6-yl)cyclopropane-1-carboxamide Chemical compound C1([C@H]2[C@H]([C@@H]2C2=CC=C3N=C(OC3=C2)C(C)C)C(=O)NO)=CC=CC=C1 RYKOEXGARNYITG-KZNAEPCWSA-N 0.000 claims 1
- LUJCLVLVLHGCKH-JCYYIGJDSA-N (1r,2r,3r)-n-hydroxy-2-phenyl-3-[4-(3-phenylmethoxyphenyl)phenyl]cyclopropane-1-carboxamide Chemical compound C1=CC([C@@H]2[C@H]([C@H]2C(=O)NO)C=2C=CC=CC=2)=CC=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LUJCLVLVLHGCKH-JCYYIGJDSA-N 0.000 claims 1
- BSODUXBASLZJEK-JHJVBQTASA-N (1r,2r,3s)-n-hydroxy-2-(2-methyl-1,3-thiazol-5-yl)-3-phenylcyclopropane-1-carboxamide Chemical compound S1C(C)=NC=C1[C@@H]1[C@@H](C=2C=CC=CC=2)[C@H]1C(=O)NO BSODUXBASLZJEK-JHJVBQTASA-N 0.000 claims 1
- DKCUOWRDLWZNHB-ZACQAIPSSA-N (1s,2r,3r)-2-(2-cyclopropylpyridin-4-yl)-3-(2-fluorophenyl)-n-hydroxycyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C=2C=C(N=CC=2)C2CC2)=CC=CC=C1F DKCUOWRDLWZNHB-ZACQAIPSSA-N 0.000 claims 1
- ZLMAVFVOVKPJRF-ZACQAIPSSA-N (1s,2r,3r)-2-(2-fluorophenyl)-3-[6-(5-fluoropyrimidin-2-yl)pyridin-3-yl]-n-hydroxycyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C=2C=NC(=CC=2)C=2N=CC(F)=CN=2)=CC=CC=C1F ZLMAVFVOVKPJRF-ZACQAIPSSA-N 0.000 claims 1
- NPACLGFXCONGNZ-OAGGEKHMSA-N (1s,2r,3r)-2-(5-chloro-2,3-dihydro-1,4-benzodioxin-7-yl)-3-(2-fluorophenyl)-n-hydroxycyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C=2C=C3OCCOC3=C(Cl)C=2)=CC=CC=C1F NPACLGFXCONGNZ-OAGGEKHMSA-N 0.000 claims 1
- FZHLQEXLYDNUOR-ZACQAIPSSA-N (1s,2r,3r)-2-[6-(5-chloropyrimidin-2-yl)pyridin-3-yl]-3-(2-fluorophenyl)-n-hydroxycyclopropane-1-carboxamide Chemical compound C1([C@@H]2[C@H]([C@@H]2C(=O)NO)C=2C=NC(=CC=2)C=2N=CC(Cl)=CN=2)=CC=CC=C1F FZHLQEXLYDNUOR-ZACQAIPSSA-N 0.000 claims 1
- CQQFBALZXRRDBM-KFWWJZLASA-N (1s,2s,3r)-2-(2-cyclopropylpyridin-4-yl)-3-(3-fluoro-5-methylthiophen-2-yl)-n-hydroxycyclopropane-1-carboxamide Chemical compound S1C(C)=CC(F)=C1[C@@H]1[C@@H](C=2C=C(N=CC=2)C2CC2)[C@@H]1C(=O)NO CQQFBALZXRRDBM-KFWWJZLASA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- QBZBWUQUCKBWFL-UHFFFAOYSA-N C1(CC1)C(=O)NC1=CC=C(C=C1)N(CCN1CCOCC1)C(C)C Chemical compound C1(CC1)C(=O)NC1=CC=C(C=C1)N(CCN1CCOCC1)C(C)C QBZBWUQUCKBWFL-UHFFFAOYSA-N 0.000 claims 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 claims 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- XOYFHZRHHSAWQK-UHFFFAOYSA-N ONC(C(C1)(C1C1=CC=CC=C1)C(C=C1)=CC=C1C1=NC=C(C(F)(F)F)C=N1)=O Chemical compound ONC(C(C1)(C1C1=CC=CC=C1)C(C=C1)=CC=C1C1=NC=C(C(F)(F)F)C=N1)=O XOYFHZRHHSAWQK-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161435678P | 2011-01-24 | 2011-01-24 | |
| US61/435,678 | 2011-01-24 | ||
| PCT/US2012/022216 WO2012103008A1 (en) | 2011-01-24 | 2012-01-23 | Histone deacetylase inhibitors and compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014511355A JP2014511355A (ja) | 2014-05-15 |
| JP2014511355A5 true JP2014511355A5 (https=) | 2015-02-19 |
Family
ID=46581126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550656A Withdrawn JP2014511355A (ja) | 2011-01-24 | 2012-01-23 | ヒストンデアセチラーゼ阻害薬並びにその組成物及び使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9765054B2 (https=) |
| EP (1) | EP2667709A4 (https=) |
| JP (1) | JP2014511355A (https=) |
| KR (1) | KR20140037821A (https=) |
| CN (1) | CN103429079A (https=) |
| AR (1) | AR085088A1 (https=) |
| AU (1) | AU2012209312A1 (https=) |
| BR (1) | BR112013018779A2 (https=) |
| CA (1) | CA2824078A1 (https=) |
| IL (1) | IL227379A0 (https=) |
| MX (1) | MX2013008629A (https=) |
| PH (1) | PH12013501561A1 (https=) |
| RU (1) | RU2013136778A (https=) |
| SG (1) | SG192061A1 (https=) |
| TW (1) | TW201245115A (https=) |
| WO (1) | WO2012103008A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9617259B2 (en) | 2013-03-14 | 2017-04-11 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| US20160031863A1 (en) * | 2013-03-14 | 2016-02-04 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2014159210A1 (en) | 2013-03-14 | 2014-10-02 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| EP2968233A4 (en) * | 2013-03-14 | 2016-08-03 | Chdi Foundation Inc | HISTON DEACETYLASE HEMMER AND COMPOSITIONS AND METHOD FOR USE THEREOF |
| JP6600319B2 (ja) | 2014-06-02 | 2019-10-30 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 |
| ITUB20155193A1 (it) * | 2015-11-03 | 2017-05-03 | Italfarmaco Spa | Sospensioni orali di Givinostat fisicamente e chimicamente stabili |
| WO2018085170A1 (en) * | 2016-11-01 | 2018-05-11 | Merck Sharp & Dohme Corp. | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2019036607A1 (en) * | 2017-08-17 | 2019-02-21 | The University Of Toledo | IMIDAZOLE ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING THEM AND METHODS OF USE THEREOF |
| KR102236356B1 (ko) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| KR20190099952A (ko) * | 2018-02-20 | 2019-08-28 | 주식회사 종근당 | 포도막염의 예방 또는 치료를 위한 조성물 |
| AU2020321955A1 (en) | 2019-07-30 | 2022-03-17 | Eikonizo Therapapeutics, Inc. | HDAC6 inhibitors and uses thereof |
| TW202120495A (zh) * | 2019-08-02 | 2021-06-01 | 美商愛彼特生物製藥股份有限公司 | 經取代環丙基—２，２＇—聯嘧啶基化合物、其類似物及其使用方法 |
| IL316201A (en) | 2022-04-08 | 2024-12-01 | Eikonizo Therapeutics Inc | Oxadiazole HDAC6 inhibitors and their uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125871B2 (en) * | 2000-05-31 | 2006-10-24 | Eli Lilly And Company | Excitatory amino acid receptor modulators |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60336850D1 (en) | 2003-01-06 | 2011-06-01 | Lilly Co Eli | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren |
| GB0316889D0 (en) | 2003-07-18 | 2003-08-20 | Univ London | Pharmaceutical agents |
| CN100546980C (zh) * | 2003-09-22 | 2009-10-07 | S*Bio私人有限公司 | 苯并咪唑衍生物:制备方法及医药应用 |
| PT1673349E (pt) * | 2003-09-22 | 2010-09-28 | S Bio Pte Ltd | Derivados benzimidazole: preparação e aplicações farmacêuticas |
| ES2384182T3 (es) | 2005-11-01 | 2012-07-02 | Sumitomo Chemical Company, Limited | Proceso para la producción de 6,6-dimetil-3-oxabiciclo[3,1,0]hexan-2-ona |
| WO2008102348A1 (en) | 2007-02-21 | 2008-08-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
| CA2683557C (en) | 2007-04-09 | 2016-10-18 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| AR091773A1 (es) | 2012-07-16 | 2015-02-25 | Chdi Foundation Inc | Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso |
-
2012
- 2012-01-20 TW TW101102386A patent/TW201245115A/zh unknown
- 2012-01-23 AR ARP120100206A patent/AR085088A1/es unknown
- 2012-01-23 RU RU2013136778/04A patent/RU2013136778A/ru not_active Application Discontinuation
- 2012-01-23 US US13/981,107 patent/US9765054B2/en active Active
- 2012-01-23 CN CN2012800111978A patent/CN103429079A/zh active Pending
- 2012-01-23 SG SG2013055504A patent/SG192061A1/en unknown
- 2012-01-23 WO PCT/US2012/022216 patent/WO2012103008A1/en not_active Ceased
- 2012-01-23 JP JP2013550656A patent/JP2014511355A/ja not_active Withdrawn
- 2012-01-23 EP EP12738982.3A patent/EP2667709A4/en not_active Withdrawn
- 2012-01-23 CA CA2824078A patent/CA2824078A1/en not_active Abandoned
- 2012-01-23 KR KR1020137021953A patent/KR20140037821A/ko not_active Withdrawn
- 2012-01-23 AU AU2012209312A patent/AU2012209312A1/en not_active Abandoned
- 2012-01-23 PH PH1/2013/501561A patent/PH12013501561A1/en unknown
- 2012-01-23 MX MX2013008629A patent/MX2013008629A/es not_active Application Discontinuation
- 2012-01-23 BR BR112013018779A patent/BR112013018779A2/pt not_active IP Right Cessation
-
2013
- 2013-07-08 IL IL227379A patent/IL227379A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511355A5 (https=) | ||
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
| US12378254B2 (en) | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | |
| RU2424242C2 (ru) | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| DK2552920T3 (en) | UNKNOWN UNKNOWN NK-3 RECEPTOR SELECTIVE ANTAGONIST RELATIONS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTOR-MEDIUM DISORDERS | |
| JP2013523884A5 (https=) | ||
| US9586962B2 (en) | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators | |
| JP6373978B2 (ja) | イミダゾピロリジノン誘導体および疾患の処置におけるその使用 | |
| CA2845578C (en) | Pyrimidine pde10 inhibitors | |
| JP2018500376A5 (https=) | ||
| JP2015522002A5 (https=) | ||
| RU2016124178A (ru) | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет | |
| MX2008012482A (es) | Compuestos de indazol. | |
| JP2016523911A5 (https=) | ||
| JP2016500073A5 (https=) | ||
| JP2017510576A5 (https=) | ||
| JP2016525092A5 (https=) | ||
| HRP20160649T1 (hr) | Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba | |
| HRP20140898T1 (hr) | Heteroaromatski derivati fenilimidazola kao inhibitori enzima pde10a | |
| TW201321369A (zh) | １，３－經取代之氮雜環丁烷ｐｄｅ１０抑制劑 | |
| HRP20121022T1 (hr) | Kondenzirani bicikliäśki pirimidini | |
| IL310330A (en) | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling | |
| EP3390387A1 (en) | Heteroarylbenzimidazole compounds | |
| JP2013518823A5 (https=) | ||
| JP2019502680A5 (https=) |